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Abstract
Tang (2018b,a) derived the exact power formulae for t tests and analysis of co-
variance (ANCOVA) in superiority, noninferiority and equivalence trials. The power
calculation in equivalence trials can be simplified by using Owen’s Q function, which
is available in standard statistical software. We extend the exact power determination
method for ANCOVA to unstratified and stratified multi-arm randomized trials. The
method is applied to the design of multi-arm trials and gold standard noninferiority
trials
Keywords: Gold standard noninferiority trial, linear contrast, multi-arm randomized
trial, pre-stratification factor
1 Introduction
Tang (2018a,b) obtained the exact power formulae for some commonly used t tests in
superiority, noninferiority (NI) and equivalence trials. The power determination for
the analysis of covariance (ANCOVA) and t-test with unequal variances in equivalence
trials involves two-dimensional numerical integration. We show that the calculation
can be simplified by using Owen’s Q function, which is available in standard statistical
software packages (e.g. SAS and R PowerTOST ). We extend the method for AN-
COVA to unstratified and stratified multi-arm randomized trials, and apply it to the
power determination for multi-arm trials and gold standard NI trials (Pigeot et al.,
2003).
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We use the same notations as Tang (2018a,b). Let t(f, λ) denote the t distri-
bution with f degrees of freedom and noncentrality parameter λ, tf,p the pth per-
centile of the central t distribution, Φ(·) the cumulative distribution function (CDF)
of N(0, 1), Ff1,f2(·) the CDF of a central F (f1, f2) distribution, and Qf (t, δ; a, b) =
1
Γ(f/2)2f/2−1
∫ b
a Φ(
tx√
f
− δ)xf−1 exp(−x22 )dx Owen’s Q function. Let ng be the number
of subjects in group g, n the total size, M0 the superiority (M0 = 0) or NI margin,
and (Ml,Mu) the lower and upper equivalence margins. Without loss of generality,
we assume high scores indicate better health.
2 Two sample t tests
Let (τˆ , n−1Vˆ ) be the estimated effect and variance with true values (τ1, n−1V ) in a test
based on the t distribution. Suppose τˆ−τ1√
n−1V
∼ N(0, 1) is independent of ξ = VˆV ∼
χ2f
f .
In superiority and NI trials, we reject the null hypothesis when t = τˆ−M0√
n−1Vˆ
> C =
tf,1−α/2. If f and V are known, the exact power is Pr
[
t(f, |τ1−M0|√
n−1V
) > C
]
, or 1 minus
the CDF of t ∼ t(f, |τ1−M0|√
n−1V
) evaluated at C.
An equivalence test is significant if both tl =
τˆ−Ml√
n−1Vˆ
> C and tu =
τˆ−Mu√
n−1Vˆ
< −C.
By the change of variable x =
√
fξ, the exact power equation (26) of Tang (2018b)
can be rearranged in terms of Owen’s Q function as
Pequi =
∫ (Mu−Ml)2
4n−1V C2
0
[
Φ(δ1 − C
√
ξ)− Φ(δ2 + C
√
ξ)
]
dG(ξ) = Qf (−C , δ2 ; 0 ,R) −Qf (C , δ1 ; 0 ,R)
(1)
where G(ξ) is the CDF of ξ ∼ χ
2
f
f , δ2 =
Ml−τ1√
n−1V
< 0, δ1 =
Mu−τ1√
n−1V
> 0 and R =
√
f(δ1−δ2)
2C .
In the t test with unequal variances [i.e. y0i
iid∼ N(µ0, σ20), y1i iid∼ N(µ1, σ21)], the
power of the superiority and NI trial is obtained from the fact (Moser et al., 1989;
Tang, 2018b) that τˆ−M0√
n−1Vˆ
h∗(u) = τˆ−M0√
n−1V
√
n−2
(n1−1)s21/σ21+(n0−1)s20/σ20
follows a noncen-
tral t(n− 2, |τ1−M0|√
n−1V
) distribution given u
Psup/ni =
∫ ∞
0
Pr
[
t
(
n− 2, |τ1 −M0|√
n−1V
)
> h(u)
]
dFn1−1,n0−1(u) (2)
where τˆ = µˆ1 − µˆ0, s2g is the sample variance in group g, n−1Vˆ = s
2
1
n1
+
s20
n0
, n−1V =
2
σ21
n1
+
σ20
n0
, u =
s21/σ
2
1
s20/σ
2
0
∼ F (n1 − 1, n0 − 1), and
h∗(u) =
√
(n− 2)[uσ21/n1 + σ20/n0]
n−1V [(n1 − 1)u+ n0 − 1] ,
f(u) =
[
uσ21/n1 + σ
2
0/n0
]2
u2σ41/[n
2
1(n1 − 1)] + σ40/[n20(n0 − 1)]
,
h(u) = tf(u),1−α
2
h∗(u).
The exact equivalence power (equation (A3) of Tang (2018b)) can be reexpressed as
Pequi =
∫ ∞
0
{Qn−2 [−h(u), δ2; 0, R(u)] −Qn−2 [h(u), δ1; 0, R(u)]} dFn1−1,n0−1(u)
(3)
where δ2 =
Ml−τ1√
n−1V
, δ1 =
Mu−τ1√
n−1V
and R(u) =
√
n−2 (δ1−δ2)
2h(u) . Please see Tang (2018b)
for numerical examples.
3 ANCOVA
Tang (2018a,b) derived the exact power formulae for ANCOVA analysis of two-arm
trials. Below we present more general results for unstratified or stratified multi-arm
randomized trials. Suppose subjects are randomized to K∗ = K+1 treatment groups
(g = 0, . . . ,K) within each of h strata. In an unstratified trial, we set h = 1. Subjects
in treatment group g are modeled by
ygi = µg+zgi1α1+. . .+zgir−1αr−1+x
′
giβ+εgi = η+δg+zgi1α1+. . .+zgir−1αr−1+x
′
giβ+εgi
where zgik (k = 1, . . . , r−1) is the indicator variable for the pre-stratification factors,
µg is the effect for treatment group g, xgi is the q × 1 vector of baseline covariates,
εgi ∼ N(0, σ2), η = µ0 and δg = µg − µ0. In general, r equals the number of
strata h. In trials with multiple stratification factors, r < h if there is no interaction
between some stratification factors. By the same arguments as the proof of equation
(15) in Tang (2018a), we obtain the variance for the linear contrast with coefficients
(l0, . . . , lK)
′
var

 K∑
g=0
lgµˆg

 = σ2Vl
(
1 +
q
n− q − r −K + 1Υ˜
)
where
∑K
g=0 lg = 0, z¯g is the mean of zgi = (zgi1 , . . . , zgir−1)
′ in group g, Szz =∑K
g=0
∑ng
i=1(zgi − z¯g)⊗2, Υ˜ is a function of the covariate xgi’s, and Vl =
∑
g l
2
g/ng +
(
∑
g lgz¯g)
′S−1zz (
∑
g lgz¯g). In a two arm trial (Tang, 2018a), Vl =
[∑h
s=1
ns1ns0
ns1+ns0
]−1
3
if there is no restriction on the stratum effect (i.e. r = h), where nsg is the number
of subjects in stratum s, treatment group g. A constant treatment allocation ratio
is commonly used in practice. Then z¯0 = . . . = z¯K and Vl =
∑
g l
2
g/ng. Let τ1 =∑
g lgµg, f = n − q − r −K, and f2 = f + 1. When xgi’s are normally distributed,
Υ˜ ∼ F (q, f2) and the exact power for the superior or NI test is
Psup/ni =
∫ ∞
0
Pr
[
t
(
f,
√
(τ1 −M0)2
σ2Vl(1 + qΥ˜/f2)
)
> tf,1−α
2
]
dFq,f2(Υ˜). (4)
Formula (4) also provides very accurate power estimate for nonnormal covariates
(Tang, 2018b). In equivalence trials, the exact power is
Pequi =
∫ ∞
0
{
Qf
[
−tf,1−α/2, δ2(Υ˜); 0, R(Υ˜)
]
−Qf
[
tf,1−α/2, δ1(Υ˜); 0, R(Υ˜)
]}
dFq,f2(Υ˜)
(5)
where δ2(Υ˜) =
Ml−τ1√
σ2Vl(1+qΥ˜/f2)
< 0, δ1(Υ˜) =
Mu−τ1√
σ2Vl(1+qΥ˜/f2)
> 0 and R(Υ˜) =
√
f(δ1−δ2)
2 tf,1−α/2
. The exact power formulae (equation (A1) of Tang (2018b), equation (30)
of Tang (2018a)) for two arm trials are equivalent to equation (5) at K = 1.
The power formulae (2), (3), (4) and (5) are of the form
∫∞
0 Pc(x)dFf1,f2(x), and
can be calculated as
P =
∫ ∞
0
Pc(x)dFf1,f2(x) =
∫ 1
0
Pc
[
F−1f1,f2(ν)
]
dν. (6)
Below we give three hypothetical examples. Sample R code is provided in the
Supplementary Material. In each example, the simulated (SIM) power is evaluated
based on 4, 000, 000 simulated datasets. There is more than 95% chance that the
SIM power lies within 0.05% of the true power. In example 1, we perform the power
calculation for a superiority trial. Subjects are randomized equally into K∗ = 3
groups (K = 2 experimental, or control treatment) stratified by gender (zgi1 = 1 for
male, 0 for female) and age (zgi2 = 1 if old, 0 otherwise). There are 6 subjects per
treatment group per stratum (n0 = n1 = n2 = 24, n = 72). There is no interaction
between age and gender (r = 3, h = 4), and the outcome is normally distributed as
ygi ∼ N [µg + 0.6 zgi1 + 0.3 zgi2 + 0.5xgi, 1]
where (µ0, µ1, µ2) = (0, 0.6, 0.9) and xgi ∼ N(0.2zgi1 + 0.4zgi2 , 1). We compare
each experimental treatment versus control treatment at the Bonferroni-adjusted one
tailed significance level of α/2 = 0.0125. The exact power by formula (4) is 78.63%
and 41.39%, and the SIM power is 78.62% and 41.39% respectively for the two tests.
Example 2 has similar setup to example 1 except that (µ0, µ1, µ2) = (0, 0.05, 0.1)
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and the sample size is 30 per group per stratum (n0 = n1 = n2 = 120, n = 360).
The aim is to establish the equivalence of each experimental treatment versus control
treatment at α/2 = 0.0125. The margin is (Ml,Mu) = (−0.5, 0.5). The exact power
by formula (5) is 79.14% and 86.72% respectively for the two tests, while the SIM
power is 79.14% and 86.71%.
In example 3, we design a three-arm “gold standard” NI trial (Pigeot et al., 2003).
It consists of placebo (g = 0), an active control treatment (g = 1) and an experimental
treatment (g = 2). The set up is similar to example 1 except that (µ0, µ1, µ2) =
(0, 1, 1.1), and the sample size is 10 per group per stratum (n0 = n1 = n2 = 40,
n = 120). Two tests are conducted at the one-sided significance level of α/2 =
0.025. Test 1 evaluates the superiority of treatment 1 over placebo. The power for
this test (exact P1 = 99.29%, SIM 99.28%) is very close to 1. In test 2, we assess
the noninferiority of treatment 2 to treatment 1 by demonstrating that treatment
2 preserves at least 50% of the efficacy of treatment 1 compared to placebo (i.e.
µ2−µ0
µ1−µ0 > 50% or µ2 − 0.5µ1 − 0.5µ0 > 0). The exact power of test 2 is P2 = 86.41%
(SIM power 86.41%). The noninferiority is claimed only if both tests are significant
(Pigeot et al., 2003), and the overall power is at least P1+P2−1 = 85.70% while the
simulated power is 85.80%.
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